Erratum: EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice (PLoS Medicine (2006) 3, 1, (e6) DOI:10.1371/journal.pmed.0030006);EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice

PLoS Medicine

Volumn 3, Issue 1, 2006, Pages 125-135

  Shir, Alexei ^a   Ogris, Manfred ^b   Wagner, Ernst ^b   Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DOUBLE STRANDED RNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MACROGOL; POLYETHYLENEIMINE; POLYINOSINIC POLYCYTIDYLIC ACID; POLYMER; RECOMBINANT EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; IMINE; MACROGOL DERIVATIVE; POLY(ETHYLENE IMINE); POLYETHYLENE DERIVATIVE; PROTEIN KINASE R;

ADENOCARCINOMA; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BRAIN TISSUE; BREAST CANCER; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG CONJUGATION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; PROTEIN TARGETING; TARGET CELL DESTRUCTION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; GENETIC TRANSFECTION; METABOLISM; METHODOLOGY; PATHOLOGY; TIME; TUMOR CELL LINE; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BYSTANDER EFFECT; CELL LINE, TUMOR; EIF-2 KINASE; EPIDERMAL GROWTH FACTOR; GLIOBLASTOMA; HUMANS; IMINES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM TRANSPLANTATION; POLY I-C; POLYETHYLENE GLYCOLS; POLYETHYLENES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, DOUBLE-STRANDED; TIME FACTORS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 32044465218     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0040266.g001     Document Type: Erratum

References (28)

1. Shir A, Levitzki A (2001) Gene therapy for glioblastoma: Future perspective for delivery systems and molecular targets. Cell Mol Neurobiol 21: 645-656.
2. Liu TF, Tatter SB, Willingham MC, Yang M, Hu JJ, et al. (2003) Growth factor receptor expression varies among high-grade gliomas and normal brain: Epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ther 2: 783-787.
3. Saunders LR, Barber GN (2003) The dsRNA binding protein family: Critical roles, diverse cellular functions. Faseb J 17: 961-983.
4. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, et al. (2003) Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8: 237-249.
5. Parker LM, Fierro-Monti I, Reichman TW, Gunnery S, Mathews MB (2001) Double-stranded RNA-binding proteins and the control of protein synthesis and cell growth. Cold Spring Harb Symp Quant Biol 66: 485-497.
6. Ogris M, Walker G, Blessing T, Kircheis R, Wolschek M, et al. (2003) Tumour-targeted gene therapy: Strategies for the preparation of ligandpolyethylene glycol-polyethylenimine/DNA complexes. J Control Release 91: 173-181.
7. Wolschek MF, Thallinger C, Kursa M, Rossler V, Allen M, et al. (2002) Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology 36: 1106-1114.
8. Shir A, Levitzki A (2002) Inhibition of glioma growth by tumour-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat Biotechnol 20: 895-900.
9. Ogris M, Carlisle RC, Bettinger T, Seymour LW (2001) Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors. J Biol Chem 276: 47550-47555.
10. Han Y, Caday CG, Nanda A, Cavenee WK, Huang HJ (1996) Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res 56: 3859-3861.
11. Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, et al. (2003) A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 63: 1834-1837.
12. Bettinger T, Carlisle RC, Read ML, Ogris M, Seymour LW (2001) Peptidemediated RNA delivery: A novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res 29: 3882-3891.
13. Lamy L, Ticchioni M, Rouquette-Jazdanian AK, Samson M, Deckert M, et al. (2003) CD47 and the 19 kDa interacting protein-3 (BNIP3) in T cell apoptosis. J Biol Chem 278: 23915-23921.
14. Iordanov MS, Ryabinina OP, Schneider P, Magun BE (2005) Two mechanisms of caspase 9 processing in double-stranded RNA- and virustriggered apoptosis. Apoptosis 10: 153-166.
15. Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R (2002) Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR. Cell 108: 221-232.
16. Kershaw MH, Wang G, Westwood JA, Pachynski RK, Tiffany HL, et al. (2002) Redirecting migration of T cells to chemokine secreted from tumours by genetic modification with CXCR2. Hum Gene Ther 13: 1971-1980.
17. Huang H, Xiang J (2004) Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumours. Int J Cancer 109: 817-825.
18. Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumour response to radiation: In vivo preclinical studies. Int J Radiat Oncol Biol Phys 58: 966-971.
19. Rae JM, Lippman ME (2004) Evaluation of novel epidermal growth factor receptor tyrosine kinase inhibitors. Breast Cancer Res Treat 83: 99-107.
20. Comis RL (2005) The current situation: Erlotinib (tarceva(r)) and gefitinib (iressa(r)) in non-small cell lung cancer. Oncologist 10: 467-470.
21. Mendelsohn J (2003) Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother 52: 342-346.
22. Study JJ (2005) HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74: 77-86.
23. Byrne BJ, Garst J (2005) Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. Curr Oncol Rep 7: 241-247.
24. Tsuchihashi Z, Khambata-Ford S, Hanna N, Janne PA (2005) Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353: 208-209.
25. Friedrich I, Eizenbach M, Sajman J, Ben-Bassat H, Levitzki A (2005) A cellular screening assay to test the ability of PKR to induce cell death in mammalian cells. Mol Ther. 12: 969-975.
26. Hogemann-Savellano D, Bos E, Blondet C, Sato F, Abe T, et al. (2003) The transferrin receptor: A potential molecular imaging marker for human cancer. Neoplasia 5: 495-506.
27. Varela M, Ranuncolo SM, Morand A, Lastiri J, De Kier Joffe EB, et al. (2004) EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas. J Surg Oncol 86: 34-40.
28. Moschos SJ, Mantzoros CS (2002) The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 63: 317-332.